Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Get your full text copy in PDF

Hospital versus home treatment of respiratory exacerbations in cystic fibrosis

Moran Lavie, Daphna Vilozni, Gil Sokol, Raz Somech, Amir Szeinberg, Ori Efrati

Med Sci Monit 2011; 17(12): CR698-703

DOI: 10.12659/MSM.882129

Background:    Treatment of respiratory exacerbations in Cystic Fibrosis (CF) is important in slowing disease progression. The treatment may be given either at home or at the hospital. The aim of our study was to compare both treatment settings.
    Material/Methods:    We retrospectively analyzed data of 139 treatments in 54 CF patients (age range12–47 y) treated for respiratory exacerbations at the hospital (n=84) and/or at home (n=55). Primary outcomes were improvement in pulmonary function tests (PFTs), weight gain and duration of treatment in relation to treatment setting. Secondary outcomes were these same parameters, but in relation to different clinical preconditions and CF-related complications.
    Results:    Mean improvement in FEV1 (% predicted) was similar between the hospital and home treatments (14.3±34.4% vs. 14.3±20.2%, respectively; NS), yet treatment duration was significantly shorter at the hospital (9.7±6.7 vs. 16.3±9.1 days, respectively; P<0.02), especially for patients colonized with Pseudomonas aeruginosa (11.1±5.5 vs. 18.0±11.0 days, respectively; p<0.01). At the hospital, a subgroup of patients with CF-related complications improved their FEV1 significantly more than those at home (13.1±19.4% vs. 1.9±14.9%, respectively; P<0.02), particularly patients with CF-related diabetes mellitus (CFRDM) (11.4±18.7% vs. 1.7±14.6%, respectively; P<0.05). Patients tended to gain more weight at the hospital compared to home treatment (1.36±4.6 kg and 0.49±3.6 kg respectively; P=0.06).
    Conclusions:    Hospital treatment for acute respiratory exacerbations in CF may be superior to home treatment, as indicated by a shorter duration of hospitalization, better improvement in FEV1 in patients with CF-related complications, CFRDM in particular and a trend toward better weight gain.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree